


## CLAIMS

1. A compound represented by the formula (I):



wherein R<sup>7</sup> and R<sup>21</sup>, the same or different, represent

- 1) a C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent,
- 2) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent,
- 3) a C<sub>7</sub> to C<sub>22</sub> aralkyloxy group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 5) RC(=Y)-O-, wherein Y represents an oxygen atom or sulfur atom, and R represents
  - a) a hydrogen atom,
  - b) a C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent,
  - c) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent,
  - d) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
  - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a  $C_7$  to  $C_{22}$  aralkyl group which may have a substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a  $C_1$  to  $C_{22}$  alkoxy group which may have a substituent,

i) an unsaturated  $C_2$  to  $C_{22}$  alkoxy group which may have a substituent,

j) a  $C_6$  to  $C_{14}$  aryloxy group which may have a substituent,

k) a  $C_3$  to  $C_{14}$  cycloalkyl group which may have a substituent,

l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

6)  $R^{S1}R^{S2}R^{S3}SiO-$ , wherein  $R^{S1}$ ,  $R^{S2}$  and  $R^{S3}$ , the same or different, represent

a) a  $C_1$  to  $C_6$  alkyl group or

b) a  $C_6$  to  $C_{14}$  aryl group,

7) a halogen atom,

8)  $R^{N1}R^{N2}N-R^M-$ , wherein  $R^M$  represents

a) a single bond,

b)  $-CO-O-$ ,

c)  $-SO_2-O-$ ,

d)  $-CS-O-$  or

e)  $-CO-NR^{N3}-$ , wherein  $R^{N3}$  represents a hydrogen atom or a  $C_1$  to  $C_6$  alkyl group which may have a

substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom, and  $R^{N1}$  and  $R^{N2}$ , the same or different, represent

- a) a hydrogen atom,
- b) a  $C_1$  to  $C_{22}$  alkyl group which may have a substituent,
- c) an unsaturated  $C_2$  to  $C_{22}$  alkyl group which may have a substituent,
- d) an aliphatic  $C_2$  to  $C_{22}$  acyl group which may have a substituent,
- e) an aromatic  $C_7$  to  $C_{15}$  acyl group which may have a substituent,
- f) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- h) a  $C_7$  to  $C_{22}$  aralkyl group which may have a substituent,
- i) a  $C_1$  to  $C_{22}$  alkylsulfonyl group which may have a substituent,
- j) a  $C_6$  to  $C_{14}$  arylsulfonyl group which may have a substituent,
- k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by  $R^{N1}$  and  $R^{N2}$  together in combination with the nitrogen atom to which  $R^{N1}$  and  $R^{N2}$  are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
- l) a 5-membered to 14-membered heteroaralkyl

group which may have a substituent,

m) a  $C_3$  to  $C_{14}$  cycloalkyl group which may have a substituent or

n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

9)  $R^{N4}SO_2-O-$ , wherein  $R^{N4}$  represents

a) a  $C_1$  to  $C_{22}$  alkyl group which may have a substituent,

b) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,

c) a  $C_1$  to  $C_{22}$  alkoxy group which may have a substituent,

d) an unsaturated  $C_2$  to  $C_{22}$  alkoxy group which may have a substituent,

e) a  $C_6$  to  $C_{14}$  aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a  $C_7$  to  $C_{22}$  aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

10)  $(R^{N5}O)_2PO-O-$ , wherein  $R^{N5}$  represents

a) a  $C_1$  to  $C_{22}$  alkyl group which may have a substituent,

b) an unsaturated  $C_2$  to  $C_{22}$  alkyl group which may have a substituent,

c) a  $C_6$  to  $C_{14}$  aryl group which may have a

substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,


e) a C<sub>7</sub> to C<sub>22</sub> aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

11) (R<sup>N1</sup>R<sup>N2</sup>N)<sub>2</sub>PO-O-, wherein R<sup>N1</sup> and R<sup>N2</sup> are the same as defined above or

12) (R<sup>N1</sup>R<sup>N2</sup>N)(R<sup>N5</sup>O)PO-O-, wherein R<sup>N1</sup>, R<sup>N2</sup> and R<sup>N5</sup> are the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

2. The compound according to claim 1 represented by the formula (I-a):



wherein R<sup>7a</sup> and R<sup>21a</sup>, the same or different, represent

1) a C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent,

2) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent,

3) a C<sub>7</sub> to C<sub>22</sub> aralkyloxy group which may have a substituent,

4) R<sup>a</sup>C(=Y<sup>a</sup>)-O-, wherein Y<sup>a</sup> represents an oxygen atom or

sulfur atom, and  $R^a$  represents

- a) a hydrogen atom,
  - b) a  $C_2$  to  $C_{22}$  alkyl group which may have a substituent,
  - c) an unsaturated  $C_2$  to  $C_{22}$  alkyl group which may have a substituent,
  - d) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,
  - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
  - f) a  $C_7$  to  $C_{22}$  aralkyl group which may have a substituent,
  - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
  - h) a  $C_1$  to  $C_{22}$  alkoxy group which may have a substituent,
  - i) an unsaturated  $C_2$  to  $C_{22}$  alkoxy group which may have a substituent,
  - j) a  $C_6$  to  $C_{14}$  aryloxy group which may have a substituent or
  - k) a 3-membered to 14-membered heteroaryloxy group which may have a substituent,
- 5)  $R^{an1}R^{an2}N-CO-O-$ , wherein  $R^{an1}$  and  $R^{an2}$ , the same or different, represent
- a) a hydrogen atom,
  - b) a  $C_1$  to  $C_{22}$  alkyl group which may have a substituent,
  - c) an unsaturated  $C_2$  to  $C_{22}$  alkyl group which

may have a substituent,

d) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C<sub>7</sub> to C<sub>22</sub> aralkyl group which may have a substituent,

g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>an1</sup> and R<sup>an2</sup> together in combination with the nitrogen atom to which R<sup>an1</sup> and R<sup>an2</sup> are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

i) a C<sub>3</sub> to C<sub>14</sub> cycloalkyl group which may have a substituent or

j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

6) R<sup>an1</sup>R<sup>an2</sup>N-SO<sub>2</sub>-O-, wherein R<sup>an1</sup> and R<sup>an2</sup> are the same as defined above,

7) R<sup>an1</sup>R<sup>an2</sup>N-CS-O-, wherein R<sup>an1</sup> and R<sup>an2</sup> are the same as defined above,

8) R<sup>an4</sup>SO<sub>2</sub>-O-, wherein R<sup>an4</sup> represents

a) a C<sub>1</sub> to C<sub>22</sub> alkyl group which may have a substituent,

b) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

c) a C<sub>1</sub> to C<sub>22</sub> alkoxy group which may have a

substituent,

d) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent,

e) a C<sub>6</sub> to C<sub>14</sub> aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C<sub>7</sub> to C<sub>22</sub> aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

9) (R<sup>an5</sup>O)<sub>2</sub>PO-O-, wherein R<sup>an5</sup> represents

a) a C<sub>1</sub> to C<sub>22</sub> alkyl group which may have a substituent,

b) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent,

c) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,

e) a C<sub>7</sub> to C<sub>22</sub> aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) (R<sup>an1</sup>R<sup>an2</sup>N)<sub>2</sub>-PO-O-, wherein R<sup>an1</sup> and R<sup>an2</sup> are the same as defined above or

11) (R<sup>an1</sup>R<sup>an2</sup>N)(R<sup>an5</sup>O)PO-O-, wherein R<sup>an1</sup>, R<sup>an2</sup> and R<sup>an5</sup> are the same as defined above; or a pharmacologically




acceptable salt thereof, or a hydrate of those.

3. The compound according to claim 1, wherein  $R^7$  and/or  $R^{21}$  represent a  $C_7$  to  $C_{22}$  aralkyloxy group which may have a substituent,  $RC(=Y)-O-$ , wherein Y and R are the same as defined above or  $R^{N1}R^{N2}N-R^M-$ , wherein  $R^M$  represents

a)  $-CO-O-$  or


b)  $-CS-O-$ , and  $R^{N1}$  and  $R^{N2}$  are the same as defined above, provided that, the leftmost bond in a) and b) is bonded to the nitrogen atom; or a pharmacologically acceptable salt thereof, or a hydrate of those.

4. The compound according to claim 1, wherein  $R^{N1}$  and  $R^{N2}$ , the same or different, represent a  $C_1$  to  $C_6$  alkyl group or  $C_6$  to  $C_{14}$  aryl group, or form, together in combination with the nitrogen atom to which  $R^{N1}$  and  $R^{N2}$  are bonded, a non-aromatic heterocyclic group selected from the group consisting of:




or a pharmacologically acceptable salt thereof, or a hydrate of those.

5. The compound according to claim 2 represented by the formula (I-b):



wherein  $R^{7b}$  and  $R^{21b}$ , the same or different, represent a  $C_7$  to  $C_{22}$  aralkyloxy group which may have a substituent, or  $R^b-C(=Y^b)-O-$ , wherein  $Y^b$  represents an oxygen atom or sulfur atom, and  $R^b$ , the same or different, represents

- a) a hydrogen atom,
- b) a  $C_2$  to  $C_6$  alkyl group which may have a substituent,
- c) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a  $C_7$  to  $C_{10}$  aralkyl group which may have a substituent,
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- h) a group of the formula (III):



wherein A)  $n$  represents an integer of 0 to 4,

$X_b$  represents

- i)  $-\text{CHR}^{\text{bN4}}-$ ,
- ii)  $-\text{NR}^{\text{bN5}}-$ ,
- iii)  $-\text{O}-$ ,
- iv)  $-\text{S}-$ ,
- v)  $-\text{SO}-$  or
- vi)  $-\text{SO}_2-$ ,

$\text{R}^{\text{bN1}}$  represents

- i) a hydrogen atom or
- ii) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,

$\text{R}^{\text{bN2}}$  represents

- i) a hydrogen atom or
- ii) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,

$\text{R}^{\text{bN3}}$  and  $\text{R}^{\text{bN4}}$ , the same or different, represent

- i) a hydrogen atom,
- ii) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,
- iii) an unsaturated  $\text{C}_2$  to  $\text{C}_{10}$  alkyl group which may have a substituent,
- iv) a  $\text{C}_6$  to  $\text{C}_{14}$  aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a  $\text{C}_7$  to  $\text{C}_{10}$  aralkyl group which may have a substituent,

vii) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

viii) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

xi) -NR<sup>bn6</sup>R<sup>bn7</sup>, wherein R<sup>bn6</sup> and R<sup>bn7</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent or

xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>bn3</sup> and R<sup>bn4</sup> together in combination with the carbon atom to which R<sup>bn3</sup> and R<sup>bn4</sup> are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and R<sup>bn5</sup> represents

i) a hydrogen atom,

ii) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

iii) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,

iv) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

v) a 5-membered to 14-membered heteroaryl group which may have a substituent,

vi) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

vii) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

viii) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>bn3</sup> and R<sup>bn5</sup> together in combination with the nitrogen atom to which R<sup>bn3</sup> and R<sup>bn5</sup> are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X<sub>b</sub>, n, R<sup>bn3</sup>, R<sup>bn4</sup> and R<sup>bn5</sup> represent the same group as defined above, and R<sup>bn1</sup> and R<sup>bn2</sup> represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>bn1</sup> and R<sup>bn2</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,


C)

X<sub>b</sub>, n, R<sup>bn2</sup>, R<sup>bn4</sup> and R<sup>bn5</sup> represent the same group as defined above, and R<sup>bn1</sup> and R<sup>bn3</sup> represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>bn1</sup> and R<sup>bn3</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

$X_b$ ,  $n$ ,  $R^{bN1}$ ,  $R^{bN4}$  and  $R^{bN5}$  represent the same group as defined above, and  $R^{bN2}$  and  $R^{bN3}$  represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by  $R^{bN2}$  and  $R^{bN3}$  together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein  $R^{bN8}$  and  $R^{bN9}$ , the same or different, represent


- i) a hydrogen atom,
- ii) a  $C_1$  to  $C_6$  alkyl group which may have a substituent,
- iii) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,
- iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- v) a  $C_7$  to  $C_{10}$  aralkyl group which may have a substituent or
- vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

6. The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a1}C(=Y^{a1})-O-$ , wherein  $Y^{a1}$  represents an oxygen atom or sulfur atom, and  $R^{a1}$

represents

- 1) a hydrogen atom,
- 2) a C<sub>2</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) a C<sub>6</sub> to C<sub>10</sub> aryl group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 5) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent or
- 6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

7. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a2</sup>C(=Y<sup>a2</sup>)-O-, wherein Y<sup>a2</sup> represents an oxygen atom or sulfur atom, and R<sup>a2</sup> represents a group of the formula (III'):



wherein A) n represents an integer of 0 to 4,  
X<sub>1</sub> represents

- 1) -CHR<sup>aN9</sup>-,
- 2) -NR<sup>aN10</sup>-,
- 3) -O-,
- 4) -S-,

5) -SO- or

6) -SO<sub>2</sub>-,

R<sup>aN6</sup> and R<sup>aN7</sup>, the same or different, represent

1) a hydrogen atom or

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

R<sup>aN8</sup> and R<sup>aN9</sup>, the same or different, represent

1) a hydrogen atom,

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,

4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) -NR<sup>aN11</sup>R<sup>aN12</sup>, wherein R<sup>aN11</sup> and R<sup>aN12</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub>



alkyl group which may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by  $R^{an8}$  and  $R^{an9}$  together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and  $R^{an10}$  represents

- 1) a hydrogen atom,
- 2) a  $C_1$  to  $C_6$  alkyl group which may have a substituent,
- 3) an unsaturated  $C_2$  to  $C_{10}$  alkyl group which may have a substituent,
- 4) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a  $C_7$  to  $C_{10}$  aralkyl group which may have a substituent,
- 7) a  $C_3$  to  $C_8$  cycloalkyl group which may have a substituent,
- 8) a  $C_4$  to  $C_9$  cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 11) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which  $R^{an10}$  is bonded, and one substituent selected from the


group consisting of R<sup>aN6</sup>, R<sup>aN7</sup> and R<sup>aN8</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R<sup>an10</sup> is bonded, and two substituents selected from the group consisting of R<sup>an6</sup>, R<sup>an7</sup> and R<sup>an8</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

B)  $n$ ,  $X_1$ ,  $R^{an7}$ ,  $R^{an9}$  and  $R^{an10}$  represent the same group as defined above, and  $R^{an6}$  and  $R^{an8}$  represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by  $R^{an6}$  and  $R^{an8}$  together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

8. The compound according to claim 6, wherein X<sub>1</sub> represents -NR<sup>an10</sup>-, wherein NR<sup>an10</sup> is the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

9. The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a3}C(=Y^{a3})-O-$ , wherein  $Y^{a3}$  represents an oxygen atom or sulfur atom, and  $R^{a3}$  represents a group of the formula (V):



wherein n represents an integer of 0 to 4,


$R^{aN13}$  represents

- 1) a hydrogen atom or
- 2) a  $C_1$  to  $C_6$  alkyl group which may have a substituent, and

$R^{aN14}$  represents

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,
- 3) a pyridinyl group which may have a substituent,
- 4) a pyrrolidin-1-yl group which may have a substituent,
- 5) a piperidin-1-yl group which may have a substituent,
- 6) a morpholin-4-yl group which may have a substituent or
- 7) a piperazin-1-yl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

10. The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a4}CO-O-$ , wherein  $R^{a4}$  represents a group of the formula (VI):



wherein  $n_1$  and  $n_2$ , the same or different, represent an

integer of 0 to 4,

$X_2$  represents

- 1)  $-\text{CHR}^{\text{aN17}}-$ ,
- 2)  $-\text{NR}^{\text{aN18}}-$ ,
- 3)  $-\text{O}-$ ,
- 4)  $-\text{S}-$ ,
- 5)  $-\text{SO}-$  or
- 6)  $-\text{SO}_2-$ ,

$\text{R}^{\text{aN15}}$  represents

- 1) a hydrogen atom or
- 2) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,

$\text{R}^{\text{aN16}}$  represents

- 1) a hydrogen atom,
- 2) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,
- 3) a  $\text{C}_6$  to  $\text{C}_{14}$  aryl group which may have a substituent or
- 4) a  $\text{C}_7$  to  $\text{C}_{10}$  aralkyl group which may have a substituent,

$\text{R}^{\text{aN17}}$  represents

- 1) a hydrogen atom,
- 2) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,
- 3) an unsaturated  $\text{C}_2$  to  $\text{C}_{10}$  alkyl group which may have a substituent,
- 4) a  $\text{C}_6$  to  $\text{C}_{14}$  aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) -NR<sup>an19</sup>R<sup>an20</sup>, wherein R<sup>an19</sup> and R<sup>an20</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent or

11) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and R<sup>an18</sup> represents

1) a hydrogen atom,

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,

4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have


a substituent,

8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

11. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a5</sup>CO-O-, wherein R<sup>a5</sup> represents a group of the formula (VII):



wherein n<sub>3</sub> represents 1 or 2,

R<sup>aN21</sup> represents

1) a hydrogen atom or

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent, and


R<sup>aN22</sup> represents

1) a hydrogen atom or

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

12. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a6</sup>CO-O-, wherein R<sup>a6</sup> represents a

group of the formula (VIII):



wherein  $n_1$  and  $n_2$ , the same or different, represent an integer of 0 to 4,

$X_3$  represents

- 1)  $-\text{CHR}^{\text{aN}25}-$ ,
- 2)  $-\text{NR}^{\text{aN}26}-$ ,
- 3)  $-\text{O}-$ ,
- 4)  $-\text{S}-$ ,
- 5)  $-\text{SO}-$  or
- 6)  $-\text{SO}_2-$ ,

$\text{R}^{\text{aN}23}$  represents

- 1) a hydrogen atom or
- 2) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,

$\text{R}^{\text{aN}24}$  represents

- 1) a hydrogen atom,
- 2) a  $\text{C}_1$  to  $\text{C}_6$  alkyl group which may have a substituent,
- 3) a  $\text{C}_6$  to  $\text{C}_{14}$  aryl group which may have a substituent or
- 4) a  $\text{C}_7$  to  $\text{C}_{10}$  aralkyl group which may have a substituent,

$\text{R}^{\text{aN}25}$  represents

- 1) a hydrogen atom,

- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,
- 4) a C<sub>1</sub> to C<sub>6</sub> alkoxy group which may have a substituent,
- 5) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 8) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 9) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 10) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 11) -NR<sup>an27</sup>R<sup>an28</sup>, wherein R<sup>an27</sup> and R<sup>an28</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and R<sup>an26</sup> represents
  - 1) a hydrogen atom,
  - 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
  - 3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which



may have a substituent,

4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,


7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

13. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a7</sup>CO-O-, wherein R<sup>a7</sup> represents a group of the formula (IX):




wherein n<sub>4</sub> represents an integer of 1 to 3, and R<sup>aN29</sup> represents

1) an amino group which may have a substituent,

3) a piperidin-1-yl group which may have a substituent or

14. The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a8}CO-O-$ , wherein  $R^{a8}$  represents a group of the formula (X):



2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

3) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent or

4) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent, and

R<sup>a</sup>N<sup>31</sup> represents

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

3) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have

a substituent,

4) a 3-membered to 8-membered non-aromatic heterocyclic group which may have a substituent,

5) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,


6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

9) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

15. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a9</sup>CO-O-, wherein R<sup>a9</sup> represents a group of the formula (XI):



wherein n<sub>4</sub> represents an integer of 1 to 3, and R<sup>aN32</sup> represents

1) a hydrogen atom,

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

3) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,


4) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

5) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

6) a pyridyl group which may have a substituent or

7) a tetrahydropyranyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

16. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a10</sup>CO-O-, wherein R<sup>a10</sup> represents a group of the formula (XII):



wherein m<sub>1</sub>, m<sub>2</sub>, m<sub>3</sub> and m<sub>4</sub>, the same or differently, represent 0 or 1,

n<sub>4</sub> represents an integer of 1 to 3, and

R<sup>aN33</sup> represents

- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,
- 4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,


7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or


10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

17. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a11</sup>CO-O-, wherein R<sup>a11</sup> represents a group of the formula (XIII):




wherein m<sub>3</sub> represents an integer of 1 to 3, and n<sub>5</sub> represents 2 or 3; or a pharmacologically acceptable salt thereof, or a hydrate of those.

18. The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a12</sup>CO-O-, wherein R<sup>a12</sup> represents a group selected from a group consisting of:



or a group selected from a group consisting of



and both of which may have a substituent on the ring;  
or a pharmacologically acceptable salt thereof, or a  
hydrate of those.

19. The compound according to claim 1, which is  
(8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-  
pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-  
18,19-epoxytricos-8,12,14-trien-11-olide,  
(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-  
21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-  
yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-  
olide and (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-  
pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-  
phenylcarbamoyloxy-18,19-epoxytricos-8,12,14-trien-11-  
olide; or a pharmacologically acceptable salt thereof,  
or a hydrate of those.

20. A medicine comprising the compound according  
to any one of claims 1 to 19, or a pharmacologically

acceptable salt thereof, or a hydrate of those as an active ingredient.

21. A pharmaceutical composition comprising the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof, or a hydrate of those as an active ingredient.

22. The medicine according to claim 20 as an agent for preventing or treating a disease for which gene expression control is effective.

23. The medicine according to claim 20 as an agent for preventing or treating a disease for which suppression of VEGF production is effective.

24. The medicine according to claim 20 as an agent for preventing or treating a disease for which an antiangiogenic effect is effective.

25. The medicine according to claim 20 as an angiogenesis inhibitor.

26. The medicine according to claim 20 as an antitumor agent.

27. The medicine according to claim 20 as a therapeutic agent for treating hemangioma.

28. The medicine according to claim 20 as a cancer metastasis inhibitor.

29. The medicine according to claim 20 as a therapeutic agent for treating retinal neovascularization or diabetic retinopathy.

30. The medicine according to claim 20 as a therapeutic agent for treating inflammatory disease.

31. The medicine according to claim 20 as a therapeutic agent for treating inflammatory diseases consisting of deforamantarthritis, rheumatoid arthritis, psoriasis and delayed hypersensitive reaction.
32. The medicine according to claim 20 as a therapeutic agent for treating atherosclerosis.
33. The medicine according to claim 20 as a therapeutic agent for treating a solid cancer.
34. The medicine according to claim 33, wherein the solid cancer is lung cancer, brain tumor, breast cancer, prostate cancer, ovarian cancer, colon cancer or melanoma.
35. The medicine according to claim 20 as a therapeutic agent for treating leukemia.
36. The medicine according to claim 20 as an antitumor agent based on gene expression control.
37. The medicine according to claim 20 as an antitumor agent based on suppression of VEGF production.
38. The medicine according to claim 20 as an antitumor agent based on an effect of angiogenesis inhibition.
39. A method for preventing or treating a disease for which gene expression control is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.



40. A method for preventing or treating a disease for which suppression of VEGF production is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.
41. A method for preventing or treating a disease for which angiogenesis inhibition is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.
42. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which gene expression control is effective.
43. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which suppression of VEGF production inhibition is effective.
44. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which angiogenesis inhibition is effective.
45. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an

167

agent for preventing or treating a solid cancer.

10/522733

10 Dec'd PCT/PTO 28 JAN 2005

SEQUENCE LISTING

<110> MERCIAN CORPORATION  
<110> Eisai Co., Ltd.  
<120> Novel bioactive compound  
<130> 03043PCT  
<160> 2  
<210> 1  
<211> 30  
<212> DNA  
<213> Artificial Sequence  
<400> 1  
atgaactttc tgctgtcttg ggtgcattgg

30

<210> 2  
<211> 29  
<212> DNA  
<213> Artificial Sequence  
<400> 2  
ctggccttgg tgaggtttgt accgcataa

29

